Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

23.88 +0.70 (+3.02%)
Streaming Delayed Price Updated: 1:38 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,139,212
Open 23.28
Bid (Size) 23.87 (200)
Ask (Size) 23.92 (700)
Prev. Close 23.18
Today's Range 22.85 - 24.95
52wk Range 6.500 - 23.38
Shares Outstanding 107,100,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan ↗
Arcus Biosciences President Sells $2 Million in Stock Under Trading Plan 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+57.8%
+57.8%
1 Month
+28.4%
+28.4%
3 Month
+135.3%
+135.3%
6 Month
+164.5%
+164.5%
1 Year
+64.0%
+64.0%

More News

Read More
News headline image
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
From Arcus Biosciences
Via Business Wire
News headline image
Analyst Expectations For Arcus Biosciences's Future ↗
Via Benzinga
Arcus Biosciences Turns Heads With 26.7-Month Survival In Gastric Cancer Study — Retail Calls It ‘Unprecedented’ ↗
Via Stocktwits
News headline image
Earnings Scheduled For August 6, 2025 ↗
Via Benzinga
News headline image
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
From Arcus Biosciences
Via Business Wire
News headline image
Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months ↗
Via Benzinga
News headline image
Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
From Arcus Biosciences, Inc.
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
How Arcus Biosciences Aims To Take On Merck In Cancer Treatment ↗
Via Investor's Business Daily
News headline image
Why Is Arcus Biosciences Stock Trading Higher On Monday? ↗
Via Benzinga
News headline image
Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday ↗
Via Benzinga
News headline image
Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
News headline image
Jim Cramer Recommends This Energy Stock, But Don't 'Bank It All' On Arcus ↗
Via Benzinga
News headline image
Gilead Lifts Annual Outlook As Yeztugo Launch Nears ↗
Via Benzinga
News headline image
Arcus (RCUS) Q2 Revenue Jumps 310% ↗
Via The Motley Fool
News headline image
Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire

Frequently Asked Questions

Is Arcus Biosciences, Inc. Common Stock publicly traded?
Yes, Arcus Biosciences, Inc. Common Stock is publicly traded.
What exchange does Arcus Biosciences, Inc. Common Stock trade on?
Arcus Biosciences, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Arcus Biosciences, Inc. Common Stock?
The ticker symbol for Arcus Biosciences, Inc. Common Stock is RCUS on the New York Stock Exchange
What is the current price of Arcus Biosciences, Inc. Common Stock?
The current price of Arcus Biosciences, Inc. Common Stock is 23.88
When was Arcus Biosciences, Inc. Common Stock last traded?
The last trade of Arcus Biosciences, Inc. Common Stock was at 11/25/25 01:38 PM ET
What is the market capitalization of Arcus Biosciences, Inc. Common Stock?
The market capitalization of Arcus Biosciences, Inc. Common Stock is 2.56B
How many shares of Arcus Biosciences, Inc. Common Stock are outstanding?
Arcus Biosciences, Inc. Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.